118 related articles for article (PubMed ID: 2140463)
1. Liposome-incorporated 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine as a slow-release anti-tumor drug depot in rat liver macrophages.
Van Borssum Waalkes M; Scherphof GL
Sel Cancer Ther; 1990; 6(1):15-22. PubMed ID: 2140463
[TBL] [Abstract][Full Text] [Related]
2. In-vitro stability and cytostatic activity of liposomal formulations of 5-fluoro-2'-deoxyuridine and its diacylated derivatives.
van Borssum Waalkes M; van Galen M; Morselt H; Sternberg B; Scherphof GL
Biochim Biophys Acta; 1993 May; 1148(1):161-72. PubMed ID: 8499464
[TBL] [Abstract][Full Text] [Related]
3. 5'-O-Palmitoyl- and 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine--novel lipophilic analogues of 5'-fluoro-2'-deoxyuridine: synthesis, incorporation into liposomes and preliminary biological results.
Schwendener RA; Supersaxo A; Rubas W; Weder HG; Hartmann HR; Schott H; Ziegler A; Hengartner H
Biochem Biophys Res Commun; 1985 Jan; 126(2):660-6. PubMed ID: 3156589
[TBL] [Abstract][Full Text] [Related]
4. In vivo distribution and antitumour activity of liposomal 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine.
Van Borssum Waalkes M; Fichtner I; Dontje B; Lemm M; Becker M; Arndt D; Scherphof GL
J Microencapsul; 1992; 9(3):335-46. PubMed ID: 1403484
[TBL] [Abstract][Full Text] [Related]
5. The antitumour effect of lipophilic derivatives of 5-fluoro-2'-deoxyuridine incorporated into liposomes.
Supersaxo A; Rubas W; Hartmann HR; Schott H; Hengartner H; Schwendener RA
J Microencapsul; 1988; 5(1):1-11. PubMed ID: 2974073
[TBL] [Abstract][Full Text] [Related]
6. Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model.
Mori A; Kennel SJ; van Borssum Waalkes M; Scherphof GL; Huang L
Cancer Chemother Pharmacol; 1995; 35(6):447-56. PubMed ID: 7882453
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells.
Koning GA; Gorter A; Scherphof GL; Kamps JA
Br J Cancer; 1999 Aug; 80(11):1718-25. PubMed ID: 10468287
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2,2-trichloroethyl)phosphate derivatives of 5-fluoro-2'-deoxyuridine and 2',5-difluoro-2'-deoxyuridine as potential dual action anticancer prodrugs.
Xia Z; Wiebe LI; Miller GG; Knaus EE
Arch Pharm (Weinheim); 1999 Aug; 332(8):286-94. PubMed ID: 10489539
[TBL] [Abstract][Full Text] [Related]
9. Immunotargeting of liposomes containing lipophilic antitumor prodrugs.
Mori A; Kennel SJ; Huang L
Pharm Res; 1993 Apr; 10(4):507-14. PubMed ID: 8483832
[TBL] [Abstract][Full Text] [Related]
10. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells.
Koning GA; Morselt HW; Velinova MJ; Donga J; Gorter A; Allen TM; Zalipsky S; Kamps JA; Scherphof GL
Biochim Biophys Acta; 1999 Aug; 1420(1-2):153-67. PubMed ID: 10446299
[TBL] [Abstract][Full Text] [Related]
11. Effect of cholesterol on the uptake and intracellular degradation of liposomes by liver and spleen; a combined biochemical and gamma-ray perturbed angular correlation study.
Roerdink FH; Regts J; Handel T; Sullivan SM; Baldeschwieler JD; Scherphof GL
Biochim Biophys Acta; 1989 Apr; 980(2):234-40. PubMed ID: 2930790
[TBL] [Abstract][Full Text] [Related]
12. Toxicity of liposomal 3'-5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in mice.
van Borssum Waalkes M; Goris H; Dontje BH; Schwendener RA; Scherphof G; Nijhof W
Anticancer Drug Des; 1998 Jun; 13(4):291-305. PubMed ID: 9627669
[TBL] [Abstract][Full Text] [Related]
13. Uptake and processing of immunoglobulin-coated liposomes by subpopulations of rat liver macrophages.
Derksen JT; Morselt HW; Scherphof GL
Biochim Biophys Acta; 1988 Sep; 971(2):127-36. PubMed ID: 2844282
[TBL] [Abstract][Full Text] [Related]
14. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model.
Storm G; Roerdink FH; Steerenberg PA; de Jong WH; Crommelin DJ
Cancer Res; 1987 Jul; 47(13):3366-72. PubMed ID: 3581073
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological activity of novel 5-fluoro-2'-deoxyuridine phosphoramidate prodrugs.
Freel Meyers CL; Hong L; Joswig C; Borch RF
J Med Chem; 2000 Nov; 43(22):4313-8. PubMed ID: 11063625
[TBL] [Abstract][Full Text] [Related]
16. Efficient intracellular delivery of 5-fluorodeoxyuridine into colon cancer cells by targeted immunoliposomes.
Koning GA; Kamps JA; Scherphof GL
Cancer Detect Prev; 2002; 26(4):299-307. PubMed ID: 12430634
[TBL] [Abstract][Full Text] [Related]
17. Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs.
Andresen TL; Davidsen J; Begtrup M; Mouritsen OG; Jørgensen K
J Med Chem; 2004 Mar; 47(7):1694-703. PubMed ID: 15027860
[TBL] [Abstract][Full Text] [Related]
18. Conversion of liposomal 5-fluoro-2'-deoxyuridine and its dipalmitoyl derivative to bile acid conjugates of alpha-fluoro-beta-alanine and their excretion into rat bile.
van Borssum Waalkes M; Kuipers F; Havinga R; Scherphof GL
Biochim Biophys Acta; 1993 Mar; 1176(1-2):43-50. PubMed ID: 8452878
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic effects of alkylphosphocholines or alkylphosphocholine-liposomes and macrophages on tumor cells.
Zeisig R; Jungmann S; Fichtner I; Daemen T; Arndt D
Anticancer Res; 1994; 14(5A):1785-9. PubMed ID: 7847811
[TBL] [Abstract][Full Text] [Related]
20. Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles.
Wang JX; Sun X; Zhang ZR
Eur J Pharm Biopharm; 2002 Nov; 54(3):285-90. PubMed ID: 12445558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]